Receptor tyrosine kinase signalling as a target for cancer intervention strategies

Endocrine-Related Cancer

Volumn 8, Issue 3, 2001, Pages 161-173

  Zwick, E ^a   Bange, J ^a   Ullrich, A ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTINEOPLASTIC AGENT; CELL PROTEIN; CELL SURFACE RECEPTOR; CETUXIMAB; EPIDERMAL GROWTH FACTOR FUSION PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; GROWTH FACTOR; INX 4437; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE RET; SCATTER FACTOR RECEPTOR; SOMATOMEDIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

APOPTOSIS; AUTOCRINE EFFECT; CANCER; CANCER GROWTH; CARCINOGENESIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG TARGETING; ENZYME REGULATION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PARACRINE SIGNALING; PROGNOSIS; PROTEIN FAMILY; RECEPTOR BINDING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; NEOPLASMS; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0034789517     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0080161     Document Type: Conference Paper

References (148)

1. Development of inhibitors for protein tyrosine kinases
2. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand - Receptor interactions
3. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms
4. Molecular targets for breast cancer therapy and prevention
5. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
6. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
7. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
8. The FGF family of growth factors and oncogenes
9. Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation
10. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo
11. Developmental roles of hgf/sf and its receptor, the c-met tyrosine kinase
12. Substrate competitive inhibitors of IGF-I receptor kinase
13. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
14. HER2/neu: Mechanisms of dimerization/oligomerization
15. Inhibition of the type I insulin-like growth factor receptor expression and signaling: Novel strategies for antimetastatic therapy
16. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
17. Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis
18. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin)
19. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
20. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
21. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines
22. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3
23. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
24. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
25. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
26. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker
27. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
28. Signaling antibodies in cancer therapy
29. Cell surface density of p 185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells
30. Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor by human tumors
31. Signaling by dual specificity kinases
32. Overexpression and amplification of the met/hgf receptor gene during the progression of colorectal cancer
33. Somatic mutations of the met oncogene are selected during metastatic spread of human hnsc carcinomas
34. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs
35. Ret in human development and oncogenesis
36. Gene expression and immunohistochemical localization of basic fibroblast growth factor in renal cell carcinoma
37. Mutations of the ret proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease
38. Therapeutic application of anti-growth factor receptor antibodies
39. The development of monoclonal antibodies for the therapy of cancer
40. Angiogenesis
41. Su5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (flk-1/kdr) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
42. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival
43. Targeted toxins
44. Mrna expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells
45. Tyrosine kinase receptor indistinguishable from the c-met protein
46. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer
47. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
48. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells
49. Epidermal growth factor binding induces a conformational change in the external domain of its receptor
50. Receptor protein-tyrosine kinases and their signal transduction pathway
51. Cell communication networks: Epidermal growth factor receptor transactivation as the paradigm for inter-receptor signal transmission
52. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
53. Constitutive expression of steel factor gene by human stromal cells
54. Dimerization of cell surface receptors in signal transduction
55. Protein tyrosine kinase receptors
56. Signal transduction via platelet-derived growth factor receptors
57. Platelet-derived growth factor and its receptor in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops
58. The role of EGFR in solid tumors and implications for therapy
59. Overexpression of c-erbB-2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
60. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma
61. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results
62. Recombinant antibody constructs in cancer therapy
63. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
64. The biology of erbB-2/neu/HER-2 and its role in cancer
65. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma
66. The mutationally activated met receptor mediates motility and metastasis
67. Insulin-like growth factors and their binding proteins: Biological actions
68. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation
69. Hepatocyte growth factor/hepatopoietin a stimulates the growth of rat kidney proximal tubule epithelial cells (RPTE), rat nonparenchymal liver cells, human melanoma cells, mouse keratinocytes and stimulates anchorage-independent growth of sv-40 transformed RPTE
70. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
71. Amplification of a novel v-erbB-related gene in a human mammary carcinoma
72. Inhibitors of tyrosine kinases
73. Protein tyrosine kinases and cancer
74. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: Evidence for autocrine and paracrine actions
75. Immunotoxins in cancer therapy
76. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor
77. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
78. ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1-Cdk2 complex formation: Receptor overexpression does not determine growth dependency
79. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway
80. Tyrphostins: Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction
81. Protein tyrosine kinase inhibitors as novel therapeutic agents
82. Tyrosine kinase inhibition: An approach to drug development
83. Cell transformation by fibroblast growth factors can be suppressed by truncated fibroblast growth factor receptors
84. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand
85. Preclinical and clinical pharmacology of antisense oligonucleotides
86. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells
87. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
88. Glioblastoma growth inhibited in vivo by a dominant-negative flk-1 mutant
89. Mutations of c-kit jm domain are found in a minority of human gastrointestinal stromal tumors
90. Immunohistochemical study of overexpression of fibroblast growth factor-1 (FGF-1), FGF-2, and FGF receptor-1 in human malignant salivary gland tumours
91. Hepatocyte growth factor (hgf) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-met
92. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor
93. Transformation of thyroid epithelium is associated with loss of c-kit receptor
94. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells
95. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: Role as anticancer agents
96. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice
97. Pathologic findings from the national surgical adjuvant breast and bowel project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer
98. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene
99. Somatic mutations in the kinase domain of the met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas
100. Hepatocyte growth factor activators, inhibitors and antagonists and their implication in cancer intervention
101. Ret mutations in human disease
102. Evidence for a role of EGF receptor in the progression of human lung carcinoma
103. Antisense therapy in cancer
104. Protein modules and signalling networks
105. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-expressing metastatic breast cancer refractory to chemotherapy treatment
106. Insulin-like growth factor binding proteins (IGFBPs) in breast cancer
107. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
108. Molecular mechanisms of developmental and tumor angiogenesis
109. Receptor tyrosine kinases as targets for drug intervention
110. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF
111. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification
112. Mouse - Human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice
113. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
114. Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors
115. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer
116. Specificity within the EGF family/ErbB receptor family signaling network
117. RTK mutations and human syndromes when good receptors turn bad
118. Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents
119. Antiangiogenic strategies and agents in clinical trials
120. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: In vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models
121. Epidermal growth factor-related peptides and their receptors in human malignancies
122. The neu oncogene: An erb-B-related gene encoding a 185,00-Mr tumour antigen
123. Germline and somatic mutations in the tyrosine kinase domain of the met proto-oncogene in papillary renal carcinomas
124. Bispecific antibodies in cancer therapy
125. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells
126. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
127. Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: Difference between neoplasms and hyperplastic lesions
128. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer
129. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
130. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
131. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development
132. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation
133. Herceptin (trastuzamab) in advanced breast cancer
134. Function of the IGF-I receptor in breast cancer
135. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator
136. Epidermal growth factor receptor viii enhances tumorigenicity in breast cancer
137. Signal transduction by receptors with tyrosine kinase activity
138. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
139. Structure, function and transforming potential of the epidermal growth factor receptor
140. The expression of the proto-oncogene c-kit in the blast cells of acute myeloblastic leukemia
141. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth
142. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
143. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk
144. Growth factor receptor tyrosine kinases
145. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
146. HER2/neu: A target for breast cancer therapy
147. Cip1/WAF1 by Akt-induced phosphorylation in HER2/nwu-overexpressing cells